Aprea Therapeutics raises $5.6 million in private placement

Aprea Therapeutics Inc. (NASDAQ: APRE) announced it has entered into a securities purchase agreement to sell 6,288,857 shares of common stock and accompanying warrants in a private placement that will generate approximately $5.6 million in gross proceeds.

The combined offering price for each share and warrant is $0.89. The warrants carry an exercise price of $0.765 per share, are immediately exercisable, and expire two years from the effectiveness date of the registration statement covering the resale of securities.

The clinical-stage biopharmaceutical company plans to use the net proceeds for general corporate purposes and research and development expenses. The offering is expected to close on or about January 30, 2026, subject to customary closing conditions.

"We believe this financing will enable us to proactively backfill patients at key dose levels in our ongoing ACESOT-1 dose-escalation study evaluating APR-1051, our WEE1 kinase inhibitor, and this may increase the likelihood of successful dose optimization," said Oren Gilad, CEO of Aprea Therapeutics.

Maxim Group LLC is serving as the sole placement agent for the offering. The securities are being sold under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under federal securities laws.

Aprea develops treatments targeting cancer cell vulnerabilities. The company's lead programs include APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for solid tumor indications.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Elroy Air wins $46M U.S. Army contract for cargo drone system
• Kairos Pharma announces 1-for-7 reverse stock split